Terms ending in 2039
Every in-force patent on Forma Therapeutics, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,532,047 | Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 10,959,994 | Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,013,733 | Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,013,734 | Treating Patients Harboring an Isocitrate DEHYDROGENASE-1 (IDH-1) Mutation In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,311,527 | Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,376,246 | Inhibiting Mutant IDH-1 In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,497,743 | Treating Patients Harboring an Isocitrate Dehydrogenase 1 (IDH-1) Mutation In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,576,906 | Inhibiting Mutant IDH-1 In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,963,956 | Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 12,053,463 | Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile In force · Medium confidence | Forma Therapeutics, Inc. | In force | Medium confidence | |
| 13 more term ends in 2039 · Pro | |||||
10 of 23 patents shown. Soonest term end first, then patent number.
Pro members see all 23.
18 of these are in force and held by Forma Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.